Skip to main content

Advertisement

Table 3 Calculated values for the Combination Index as a growth inhibitory effect of combination treatment with Herceptin® and Cisplatin in gastric cancer cell lines

From: Correlation between HER-2/neu(erbB-2) expression level and therapeutic effect of combination treatment with HERCEPTIN and chemotherapeutic agents in gastric cancer cell lines

YBC-2 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
CDDP     4.512 0.921 0.882
HER     1201.0 0.316 0.915
CDDP + HER 1.375 2.707 5.337 2.232 0.587 0.965
Diagnosis combined effect antagonism antagonism antagonism    
YBC-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
CDDP     30.733 2.227 0.929
HER     46.063 0.623 0.970
CDDP + HER 0.274 0.110 0.054 12.091 1.472 0.998
Diagnosis combined effect synergy synergy synergy    
NCI-N87 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
CDDP     45.86 0.53 0.93
HER     1.13E + 05 0.19 0.63
CDDP + HER 0.03 0.01 0.01 0.83 0.88 0.96
Diagnosis combined effect synergy synergy synergy    
U-87 MG Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
CDDP     5.65 1.08 0.98
HER     1845.53 0.46 0.86
CDDP + HER 9.18 9.85 10.58 2.56 1.01 0.99
Diagnosis combined effect antagonism antagonism antagonism    
SK-BR-3 Combination Index Value Parameter (μM)
Drug ED50 ED75 ED90 Dm m r
CDDP     20.63 2.42 0.94
HER     1.42E + 06 0.05 0.43
CDDP + HER 0 0 0 1.45 1.44 0.99
Diagnosis combined effect synergy synergy synergy    
  1. CDDP, Cisplatin; HER, Herceptin.